MCID: IRS003
MIFTS: 25

Iris Disease

Categories: Eye diseases

Aliases & Classifications for Iris Disease

MalaCards integrated aliases for Iris Disease:

Name: Iris Disease 12 15
Iris Diseases 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:240
MeSH 44 D007499
NCIt 50 C34737
SNOMED-CT 68 85478004
UMLS 73 C0022078

Summaries for Iris Disease

MalaCards based summary : Iris Disease, also known as iris diseases, is related to aniridia 2 and traumatic glaucoma. An important gene associated with Iris Disease is PAX6 (Paired Box 6), and among its related pathways/superpathways is Mesodermal Commitment Pathway. The drugs Timolol and Ganciclovir have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 76 In humans and most mammals and birds, the iris (plural: irides or irises) is a thin, circular structure... more...

Related Diseases for Iris Disease

Diseases related to Iris Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 aniridia 2 10.2 PAX6 ELP4
2 traumatic glaucoma 10.2 PHEX OPTN
3 chronic closed-angle glaucoma 10.2 PHEX OPTN
4 glaucoma, normal tension 10.2 OPTN LOXL1
5 acute closed-angle glaucoma 10.2 PEX19 OPTN
6 isolated aniridia 10.2 PAX6 FOXC1
7 glaucoma-related pigment dispersion syndrome 10.2 PITX2 LOXL1
8 congenital aphakia 10.2 PAX6 OPTN
9 anterior segment dysgenesis 1 10.2 PITX2 PAX6
10 low tension glaucoma 10.2 PHEX OPTN
11 enthesopathy 10.2 PHEX MRAP
12 ritscher-schinzel syndrome 10.1 OPTN FOXC1
13 glaucoma, primary open angle 10.1 PHEX OPTN LOXL1
14 anterior segment dysgenesis 4 10.1 PITX2 FOXC1
15 hemihyperplasia, isolated 10.1 WT1 IGF2
16 chorioretinitis 10.1 OPTN MRAP
17 blood group, globoside system 10.1 OPTN MRAP
18 endophthalmitis 10.1 OPTN MRAP
19 vernal conjunctivitis 10.1 OPTN LOXL1
20 morgagni cataract 10.1 PHEX CRYAA
21 congenital mesoblastic nephroma 10.1 WT1 IGF2
22 conjunctival degeneration 10.1 PAX6 CRYAA
23 persistent hyperplastic primary vitreous 10.1 PITX2 FOXC1
24 axenfeld-rieger syndrome, type 3 10.1 PITX2 PAX6 FOXC1
25 intestinal atresia 10.1 PITX2 PAX6 FOXC1
26 glaucomatocyclitic crisis 10.1 PITX2 MRAP
27 hereditary wilms' tumor 10.1 WT1 PAX6 IGF2
28 axenfeld-rieger syndrome, type 1 10.1 PITX2 PAX6
29 peters-plus syndrome 10.1 PITX2 PAX6 FOXC1
30 purulent endophthalmitis 10.1 OPTN MRAP
31 isolated foveal hypoplasia 10.1 SLC38A8 PAX6
32 pinguecula 10.0 PAX6 CRYAA
33 hallermann-streiff syndrome 10.0 OPTN IGF2
34 hydrophthalmos 10.0 PITX2 OPTN FOXC1
35 axenfeld-rieger syndrome, type 2 10.0 PITX2 OPTN FOXC1
36 primary congenital glaucoma 10.0 PITX2 OPTN FOXC1
37 iridocyclitis 10.0 MRAP CRYAA
38 congenital nystagmus 10.0 SLC38A8 PAX6
39 axenfeld-rieger syndrome 10.0 PITX2 PAX6 OPTN FOXC1
40 glaucoma 3, primary congenital, a 10.0 PITX2 PAX6 OPTN FOXC1
41 rhabdoid tumor predisposition syndrome 1 10.0 WT1 IGF2
42 adamantinoma of long bones 9.9 PITX2 PAX6 OPTN FOXC1
43 rubeosis iridis 9.9 IGF2 CRYAA
44 juvenile glaucoma 9.9 PITX2 PHEX PAX6 OPTN FOXC1
45 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 9.8 WT1 PAX6 IGF2 FSHB ELP4
46 lens disease 9.8 PHEX PEX19 PAX6 OPTN CRYAA
47 phacogenic glaucoma 9.8 PHEX PEX19 OPTN LOXL1 CRYAA
48 uveal disease 9.8 PHEX PEX19 PAX6 OPTN MRAP LOXL1
49 wilms tumor 1 9.8 WT1 PAX6 IGF2
50 cataract 9.8 PITX2 PAX6 LOXL1 ELP4 CRYAA

Graphical network of the top 20 diseases related to Iris Disease:



Diseases related to Iris Disease

Symptoms & Phenotypes for Iris Disease

MGI Mouse Phenotypes related to Iris Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.73 FOXC1 IGF2 LOXL1 PAX6 PHEX PITX2
2 endocrine/exocrine gland MP:0005379 9.7 FOXC1 FSHB IGF2 PAX6 PHEX PITX2
3 reproductive system MP:0005389 9.5 FOXC1 FSHB IGF2 LOXL1 PAX6 PITX2
4 respiratory system MP:0005388 9.1 FOXC1 IGF2 LOXL1 PAX6 PITX2 WT1

Drugs & Therapeutics for Iris Disease

Drugs for Iris Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Timolol Approved Phase 4,Phase 3,Not Applicable 26839-75-8 33624 5478
2
Ganciclovir Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 82410-32-0 3454
3
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
4
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
6
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
8
Certolizumab pegol Approved Phase 4 428863-50-7
9
Maleic acid Experimental Phase 4 110-16-7 444266
10
Bromfenac Approved July 1997 Phase 4 91714-94-2 60726
11 Adrenergic Antagonists Phase 4,Phase 3,Not Applicable
12 Adrenergic beta-Antagonists Phase 4,Phase 3,Not Applicable
13 Anti-Arrhythmia Agents Phase 4,Phase 3,Not Applicable
14 Neurotransmitter Agents Phase 4,Phase 3,Not Applicable
15 Adrenergic Agents Phase 4,Phase 3,Not Applicable
16 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Ganciclovir triphosphate Phase 4,Phase 2,Phase 3,Not Applicable
21 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
23 Carbonic Anhydrase Inhibitors Phase 4,Not Applicable
24 calcium heparin Phase 4
25 Anti-Bacterial Agents Phase 4,Phase 1
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antirheumatic Agents Phase 4,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics, Non-Narcotic Phase 4,Not Applicable
36 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Analgesics Phase 4,Not Applicable
40 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antibiotics, Antitubercular Phase 4,Phase 1
44 Melanocyte-Stimulating Hormones Phase 4,Not Applicable
45 Adrenocorticotropic Hormone Phase 4,Not Applicable
46 beta-endorphin Phase 4,Not Applicable
47 Immunologic Factors Phase 4,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
49
Pilocarpine Approved, Investigational Phase 3,Not Applicable 54-71-7, 92-13-7 5910
50
Fluprednisolone Approved Phase 3,Phase 2 53-34-9

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
2 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
3 Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties Completed NCT01767012 Phase 4
4 Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery Completed NCT02137161 Phase 4 Dexamethasone+Tobramycin eye drop;Bromfenac eye drop
5 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
6 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
7 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
8 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Terminated NCT02769702 Phase 4 Acthar
9 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
10 A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
11 Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis Completed NCT02517619 Phase 3 Dexamethasone Phosphate Ophthalmic Solution;Prednisolone Acetate Ophthalmic (1%)
12 Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis Completed NCT01505088 Phase 3 40 mg/mL Dexamethasone phosphate ophthalmic solution;Prednisolone Acetate (1%) Eyedrops;100 mM sodium citrate buffer solution;Placebo Eyedrops
13 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
14 Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension Completed NCT01126203 Phase 3
15 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination Completed NCT00331240 Phase 3 travoprost/timolol fixed combination;placebo (artificial tears)
16 SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis. Recruiting NCT03131154 Phase 3 ADX-102 Ophthalmic Solution (0.5%);Vehicle of ADX-102 Ophthalmic Solution
17 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes Not yet recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
18 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis Not yet recruiting NCT03576898 Phase 2, Phase 3 Topical ganciclovir versus oral valganciclovir versus placebo
19 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis Terminated NCT00333996 Phase 2, Phase 3 Dexamethasone
20 Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis Completed NCT02482129 Phase 2 LME636 60 mg/mL ophthalmic solution;Dexamethasone 0.1% ophthalmic solution;LME636 Vehicle
21 A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis Completed NCT02406209 Phase 2 NS2;Prednisolone acetate ophthalmic suspension (1%)
22 Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis Completed NCT02309385 Phase 1, Phase 2 8% Dexamethasone Sodium Phosphate - Visulex;15% Dexamethasone Sodium Phosphate - Visulex;Prednisolone Acetate (1%) Eye Drops
23 Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis Completed NCT00823173 Phase 2
24 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed NCT00405496 Phase 2 Difluprednate Ophthalmic Emulsion
25 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma Completed NCT01936389 Phase 2 AR-12286
26 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
27 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis Completed NCT00130637 Phase 2 Daclizumab
28 Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy Recruiting NCT03575130 Phase 2 Ripasudil eye drops;Optive eye drops
29 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) Active, not recruiting NCT02653391 Phase 1, Phase 2 Elamipretide 1.0% Ophthalmic Solution;Elamipretide 3.0% Ophthalmic Solution
30 Study of Ataluren in Participants With Nonsense Mutation Aniridia Active, not recruiting NCT02647359 Phase 2 Ataluren;Placebo
31 Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti Completed NCT00876434 Phase 1 Sirolimus
32 Quality of Life and Visual Function in Uveitis Patients Unknown status NCT00407316
33 Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma Unknown status NCT02679482
34 Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study Unknown status NCT02155478 Not Applicable
35 Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis Unknown status NCT01486693
36 Acute Anterior Uveitis: Psychic Burden and Pain Unknown status NCT01156285
37 LOXL1 Polymorphism in Pseudoexfoliation Syndrome Unknown status NCT01515735
38 The International Collaborative Exfoliation Syndrome Treatment Study Unknown status NCT00804115 Not Applicable Latanoprost with Pilocarpine vs Timolol or Cosopt
39 Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty Unknown status NCT00744796 Not Applicable
40 Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome Unknown status NCT01455168
41 Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT02020044 Not Applicable
42 Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis Unknown status NCT02879084
43 The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure Completed NCT02165631
44 Adherence With Fixed Versus Unfixed Glaucoma Therapy Completed NCT01281020
45 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed NCT00121147 Not Applicable Travatan;Azopt;Alphagan P
46 Micropulse Laser Trabeculoplasty as Adjunctive Treatment in Patients With Pseudoexfoliation Glaucoma Completed NCT03483402 Not Applicable
47 Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis Completed NCT01647529 Not Applicable Ganciclovir
48 Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty Completed NCT00485108 Not Applicable prednisolone 1%;ketorolac 0.5%;Artificial Tears (Methyl cellulose drops)
49 PEMF: an Adjunct Therapy for Anterior Uveitis Completed NCT01154010 Not Applicable
50 Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome Completed NCT01298895

Search NIH Clinical Center for Iris Disease

Cochrane evidence based reviews: iris diseases

Genetic Tests for Iris Disease

Anatomical Context for Iris Disease

MalaCards organs/tissues related to Iris Disease:

41
Eye, Retina, Bone

Publications for Iris Disease

Variations for Iris Disease

Expression for Iris Disease

Search GEO for disease gene expression data for Iris Disease.

Pathways for Iris Disease

Pathways related to Iris Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 ELP4 FOXC1 PAX6 PITX2

GO Terms for Iris Disease

Cellular components related to Iris Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.23 CRYAA ELP4 FOXC1 OPTN PAX6 PEX19

Biological processes related to Iris Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.73 FOXC1 FSHB IGF2 PAX6 PITX2 WT1
2 positive regulation of gene expression GO:0010628 9.67 FOXC1 FSHB PAX6 WT1
3 skeletal system development GO:0001501 9.5 FOXC1 IGF2 PHEX
4 eye development GO:0001654 9.4 FOXC1 PAX6
5 iris morphogenesis GO:0061072 9.16 PAX6 PITX2
6 lacrimal gland development GO:0032808 8.96 FOXC1 PAX6
7 camera-type eye development GO:0043010 8.92 FOXC1 PAX6 PITX2 WT1

Molecular functions related to Iris Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 8.8 FOXC1 PAX6 WT1

Sources for Iris Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....